Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C26H36N2O5 |
| Molecular Weight | 456.5744 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C=C(CCN(C)CCCN2CCC3=CC(OC)=C(OC)C=C3CC2=O)C=C1
InChI
InChIKey=KEDQCFRVSHYKLR-UHFFFAOYSA-N
InChI=1S/C26H36N2O5/c1-27(13-9-19-7-8-22(30-2)23(15-19)31-3)11-6-12-28-14-10-20-16-24(32-4)25(33-5)17-21(20)18-26(28)29/h7-8,15-17H,6,9-14,18H2,1-5H3
| Molecular Formula | C26H36N2O5 |
| Molecular Weight | 456.5744 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15648302 | https://www.ncbi.nlm.nih.gov/pubmed/14561092 |
https://www.ncbi.nlm.nih.gov/pubmed/19093365
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15648302 | https://www.ncbi.nlm.nih.gov/pubmed/14561092 |
https://www.ncbi.nlm.nih.gov/pubmed/19093365
Zatebradine is a bradycardic compound that blocks hyperpolarization-activated inward current (If) through cyclic nucleotide-gated cation (HCN) channels in sinoatrial node cells. Additionally, it can block voltage-gated outward K+ (IK) currents and related neuronal hyperpolarization-activated inward current (Ih) channels but exhibits little or no activity for L-type Ca2+ (ICa) currents. When assessed through telemetric ECG recording in mice, zatebradine reduced heart rate from 600 to 200 beats per minute with an ED50 value of 1.8 mg/kg and induced increasing arrhythmia at concentrations >10 mg/kg.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity. | 2013-03 |
|
| Bradycardic and proarrhythmic properties of sinus node inhibitors. | 2006-04 |
|
| Increases in inotropic state without change in heart rate: combined use of dobutamine and zatebradine in conscious dogs. | 1996-12-05 |
|
| Effects of zatebradine on ouabain-, two-stage coronary ligation- and epinephrine-induced ventricular tachyarrhythmias. | 1996-04-11 |
|
| Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The Zatebradine Study Group. | 1995-08 |
|
| Zatebradine attenuates cyclic AMP-related positive chronotropic but not inotropic responses in isolated, perfused right atria of the dog. | 1995-01 |
|
| Zatebradine, a specific bradycardic agent, enhances the positive inotropic actions of dobutamine in ischemic myocardium. | 1994-01 |
|
| Effect of zatebradine on contractility, relaxation and coronary blood flow. | 1993-02 |
|
| Specific bradycardic agents, a new therapeutic modality for anesthesiology: hemodynamic effects of UL-FS 49 and propranolol in conscious and isoflurane-anesthetized dogs. | 1987-11 |
|
| Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent". | 1984-09-03 |
Sample Use Guides
Rats were treated with Zatebradine at dose 3 mg/kg i.v
Route of Administration:
Intravenous
Sinoatrial node pacemaker cells were isolated enzymatically from rabbit hearts. The inward currents, elicited by hyperpolarizing pulses of 2000 ms from a holding potential of −40 mV to −140 mV in 10 mV increments and then clamp back to 0 mV for 1000 ms, were recorded first in the absence and then in the presence of zatebradine or CsCl. The established If blockers zatebradine (1 mkM) and CsCl (2 mM) inhibited If by 63.7 ± 8.4% and 91.8 ± 5.6%, respectively
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:06:29 GMT 2025
by
admin
on
Mon Mar 31 18:06:29 GMT 2025
|
| Record UNII |
TV27RY5876
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47793
Created by
admin on Mon Mar 31 18:06:29 GMT 2025 , Edited by admin on Mon Mar 31 18:06:29 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C66687
Created by
admin on Mon Mar 31 18:06:29 GMT 2025 , Edited by admin on Mon Mar 31 18:06:29 GMT 2025
|
PRIMARY | |||
|
C043636
Created by
admin on Mon Mar 31 18:06:29 GMT 2025 , Edited by admin on Mon Mar 31 18:06:29 GMT 2025
|
PRIMARY | |||
|
m11583
Created by
admin on Mon Mar 31 18:06:29 GMT 2025 , Edited by admin on Mon Mar 31 18:06:29 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID1048413
Created by
admin on Mon Mar 31 18:06:29 GMT 2025 , Edited by admin on Mon Mar 31 18:06:29 GMT 2025
|
PRIMARY | |||
|
65637
Created by
admin on Mon Mar 31 18:06:29 GMT 2025 , Edited by admin on Mon Mar 31 18:06:29 GMT 2025
|
PRIMARY | |||
|
TV27RY5876
Created by
admin on Mon Mar 31 18:06:29 GMT 2025 , Edited by admin on Mon Mar 31 18:06:29 GMT 2025
|
PRIMARY | |||
|
CHEMBL69679
Created by
admin on Mon Mar 31 18:06:29 GMT 2025 , Edited by admin on Mon Mar 31 18:06:29 GMT 2025
|
PRIMARY | |||
|
100000079372
Created by
admin on Mon Mar 31 18:06:29 GMT 2025 , Edited by admin on Mon Mar 31 18:06:29 GMT 2025
|
PRIMARY | |||
|
SUB00143MIG
Created by
admin on Mon Mar 31 18:06:29 GMT 2025 , Edited by admin on Mon Mar 31 18:06:29 GMT 2025
|
PRIMARY | |||
|
85175-67-3
Created by
admin on Mon Mar 31 18:06:29 GMT 2025 , Edited by admin on Mon Mar 31 18:06:29 GMT 2025
|
PRIMARY | |||
|
6240
Created by
admin on Mon Mar 31 18:06:29 GMT 2025 , Edited by admin on Mon Mar 31 18:06:29 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
